Introduction {#dmy046s6}
============

The hypothalamic-pituitary-gonadal (HPG) axis plays a critical role in maintaining the normal function of the reproductive system in adolescents ([@dmy046C61]). This axis is governed by the pulsatile secretion of gonadotropin-releasing hormone (GnRH) which, in turn, stimulates the secretion of gonadotropins (FSH and LH). The pulsatile secretion of GnRH/gonadotropins is modulated by feedback inhibition from the target gonadal hormones ([@dmy046C46]). During the periovulatory stage, the surge secretion of GnRH/gonadotropins is induced by the positive feedback of serum estrogen ([@dmy046C41]), which consequently triggers ovulation in female mammals ([@dmy046C80]). Being the upstream regulator of pulsatile and surge GnRH release, kisspeptin has been much heralded in the past decade, with its fundamental roles in regulating female reproduction in several aspects, which include gonadotropin secretion, puberty onset, brain sex differentiation and ovulation ([@dmy046C102]; [@dmy046C97]; [@dmy046C50]). Kisspeptin neurons are located within two regions in the hypothalamus, the anteroventral periventricular nucleus (AVPV) and arcuate nucleus (ARC), which are responsible for mediating the positive and negative feedback effects of estrogen on GnRH/gonadotropin secretion, respectively ([@dmy046C115]; [@dmy046C132]). Specifically, estrogen binds to ERα on kisspeptin neurons in the ARC or infundibular nucleus, which further inhibit kisspeptin and subsequently the GnRH release ([@dmy046C115]). Additionally, estrogen exerts positive feedback (also mediated via ERα) on kisspeptin neurons in the AVPV nucleus, which accounts for the LH surge in the menstrual cycle ([@dmy046C132]).

In many mammals, kisspeptins function to stimulate the release of GnRH (and subsequently the secretion of FSH and LH) by binding to the kisspeptin receptor (KISS1R), which is a G-protein-coupled receptor. Notably, inactivating mutations of either *KISS1* or *KISS1R* lead to the phenotype of hypogonadotropic hypogonadism in humans and mice ([@dmy046C128]; [@dmy046C129]; [@dmy046C104]; [@dmy046C88]; [@dmy046C133]). Additionally, recent studies have indicated the potential pathophysiological roles of extra-hypothalamic kisspeptins in the central and peripheral regulation of the activity of diverse systems ([@dmy046C130]; [@dmy046C98]; [@dmy046C65]; [@dmy046C23]; [@dmy046C135]). Outside the hypothalamic area, kisspeptins and their putative receptor KISS1R have been identified across different types of tissues, particularly those involved in reproductive and metabolic functions, including the hippocampus, forebrain, ovary, uterus, placenta, testis, adipose tissue, pancreas and liver ([@dmy046C90]; [@dmy046C2]; [@dmy046C13]; [@dmy046C14]; [@dmy046C98]; [@dmy046C140]; [@dmy046C146]; [@dmy046C33]). Indeed, kisspeptins can exert several different physiological actions on various types of tissues in an autocrine/paracrine manner. During the processes of implantation and placentation, many studies have shown that the functional form of the kisspeptin/KISSR system is expressed at the maternal-fetal interface, including the endometrial and placental tissues of various species, including humans ([@dmy046C112]; [@dmy046C14]; [@dmy046C146]). Furthermore, recent studies have indicated that locally expressed kisspeptin/KISS1R directly participates in various physiological and pathophysiological activities at the maternal-fetal interface.

This review will mainly focus on the available literature related to the pathophysiological roles of the kisspeptin/KISS1R system in regulating the processes of implantation and placentation. We summarize our current knowledge regarding the underlying mechanisms by which kisspeptin exerts its cellular activities in the processes of implantation, embryo development and placentation. We will also mention the potential implications of kisspeptins in the prediction and diagnosis of early pregnancy-related disorders.

Methods {#dmy046s7}
=======

Literature searches using either PubMed or Google Scholar were performed to review articles written in English focusing on the advancement of kisspeptins and KISS1R in embryo implantation, placentation and early pregnancy-related complications. The search included human and other mammalian studies starting from the initial identification of kisspeptin in 1996 until July 2018. Search terms included 'kisspeptin', 'metastin', 'GPR54' and 'KISS1R'. We also combined the findings that best aligned with the themes of 'implantation', 'uterus', 'pregnancy', 'placenta', 'miscarriage' and 'gestational trophoblastic neoplasia'. The search strategy and study selection for the references included in this review are presented in [Supplemental Figure S1](#sup1){ref-type="supplementary-material"}.

A short review of the *KISS1* gene and peptide and its receptor {#dmy046s8}
===============================================================

Kisspeptin (a 145-amino acid polypeptide) and its encoding gene *KISS1* were originally identified as a human metastasis suppressor (and a gene) of malignant melanoma in Hershey, Pennsylvania, the USA, the hometown of the famous chocolate Hershey's kisses ([@dmy046C68]). The name of KISS1 was derived from these sweets, with the terminology 'SS' in KISS1 indicating the 'suppressor sequence'. In humans, the *KISS1* gene that encodes kisspeptins is located on the long (q) arm of chromosome 1 at q32 ([@dmy046C136]). Initially, this gene encodes an intermediate 145-amino-acid prepropeptide, which is unstable and biologically inactive. The prepropeptide is then cleaved into four biologically active peptides distinguished by their number of amino acids: kisspeptin-10, 13, 14 and 54 (52 in rodent animals) (Figure [1](#dmy046F1){ref-type="fig"}). Sharing a common characteristic of the RF-amide signal peptide, all of these peptides have a C-terminal region that contains an Arg-Phe-NH2 motif, which allows these peptides to bind to and fully activate KISS1R. Because of the structural similarities and their common origin derived from the prepropeptide, the term 'kisspeptins' is now globally used to describe this family of peptides ([@dmy046C64]; [@dmy046C42]; [@dmy046C97]).

![**The major structure of kisspeptins in humans, the peptides encoded by the** ***KISS1*** **gene**. All kisspeptins are the products generated by the cleavage of a common precursor named prepro-kisspeptin. The prepro-kisspeptin is a 145-amino acid peptide, which is further cleaved into the following four peptides with lower molecular weights: KP-54, KP-14, KP-13 and KP-10. All kisspeptins contain the RF-amide motif that can bind and activate KISS1R. This figure is modified from [@dmy046C97]; [@dmy046C50].](dmy046f01){#dmy046F1}

To acknowledge its metastasis inhibitory properties, kisspeptin-54 was initially termed 'metastin'. This peptide was considered the major product of the human *KISS1* gene, and it could be further cleaved into 14, 13 and 10 amino acid peptides ([@dmy046C90]) (Figure [1](#dmy046F1){ref-type="fig"}). However, the largest proteolytic product of the kisspeptin precursor comprises 52 amino acids, and the terminal RF-amide signature is substituted by an Arg-Tyr-NH2 motif in rats and mice ([@dmy046C97]). In both humans and rats, the kisspeptin-54/52, -14, -13 and a shorter peptide kisspeptin-10 have the same affinity and binding efficacy onto their receptor, indicating that the C-terminal region of these peptides contributes to the high-affinity binding and the activation of KISS1R ([@dmy046C64]).

KISS1R belongs to the G-protein-coupled receptor family that was first identified as an orphan receptor in the rat brain. This seven-transmembrane receptor is structurally similar to the transmembrane region of galanin receptors, with \~40% sequence identity ([@dmy046C67]). Subsequently, the orthologue gene of KISS1R in humans was cloned and recognized as a putative receptor for *KISS1* gene-derived peptides ([@dmy046C83]; [@dmy046C90]). In terms of nomenclature, KISS1R has different names, including KISS1R, AXOR12, GPR54, CPPB1, hOT7T175 and HH8 because various groups of researchers have independently identified its presence or studied its physiological roles ([@dmy046C67]; [@dmy046C64]; [@dmy046C83]; [@dmy046C90]; [@dmy046C42]).

Kisspeptin signaling pathways {#dmy046s9}
=============================

KISS1R is a G-protein-coupled receptor that belongs to the subgroup of typical Gq/11 protein-associated receptors. Following the stimulation of KISS1R by kisspeptin peptides, the phosphorylated Gq/11 protein activates phospholipase C (PLC)-β, leading to the activation or formation of various second messengers, including those involved in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), the accumulation of inositol-(1,4,5)-triphosphate (IP3), diacylglycerol and protein kinase C (PKC) and the mobilization and release of intracellular Ca^2+^ into the cytoplasm ([@dmy046C90]; [@dmy046C116]; [@dmy046C57]) (Figure [2](#dmy046F2){ref-type="fig"}).

![**Kisspeptin/KISS1R signaling and potential functions at a glance**. KISS1R is a seven-transmembrane domain, Gq/11-coupled receptor. Upon binding of kisspeptin, the intracellular portion of KISS1R phosphorylates Gq/11. The α-subunit of Gq/11 activates PLC, which subsequently cleaves PIP2 into IP3 and DAG. IP3 promotes intracellular Ca^2+^ release from the endoplasmic reticulum, while DAG activates a signaling cascade by phosphorylating PKC. PKC activation induces the phosphorylation of ERK1/2 and p38. In addition, activation of KISS1R recruits arrestin-1 and -2, which down-regulates and up-regulates phosphorylated ERK1/2 levels, respectively. The activation of KISS1R can also stimulate the phosphorylation of PI3K/Akt, and suppress the phosphorylation of PI3K/Akt by blocking the prometastatic chemokine receptor CXCR4 (the receptor for the chemokine stromal cell-derived factor 1) signaling. These signals act on downstream pathways, including NF-κB, MMPs and VEGF, to promote hormone secretion and apoptosis and inhibit metastasis, migration, angiogenesis and proliferation. DAG, diacylglycerol; ERK1/2, extracellular signal-regulated kinase; IP3, inositol 1,4,5-triphosphate; PI3K, phosphatidylinositol-3-kinase; MMPs, matrix metalloproteinases; NF-κB, nuclear factor κB; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; VEGF, vascular endothelial growth factor.](dmy046f02){#dmy046F2}

Apart from the PLC--PKC--Ca^2+^ pathway, other intracellular transduction pathways are also activated in response to kisspeptin stimulation. In many cell types, the phosphorylation of ERK1/2 is thought to be the most conserved kinase signal. However, some cell types that show the activation of ERK1/2 do not have stable p38 MAPK and PI3K/Akt activation in response to kisspeptins ([@dmy046C101]; [@dmy046C12]; [@dmy046C95]). For instance, treatment with kisspeptin-10 induces strong and sustained phosphorylation of ERK1/2 but very weak phosphorylation of p38 and no phosphorylation of stress-activated protein kinase/c-Jun NH~2~-terminal kinase in Chinese hamster ovary (CHO)-K1 cells ([@dmy046C64]). Another example is that kisspeptin activates ERK1/2 signaling without significant effects on P38 phosphorylation in rat luteal cells ([@dmy046C95]). In many mammalian cells, the kisspeptin-induced activation of Kiss1r can recruit β-arrestin 1 and β-arrestin 2 to the plasma membrane, which further increases the intracellular level of phosphorylated ERK1/2. In particular, β-arrestin 2 potentiates Kiss1r signaling to ERK, but β-arrestin 1 inhibits it ([@dmy046C92]; [@dmy046C124]; [@dmy046C40]). Additionally, activation of PKC is required to promote the ERK1/2 signaling cascade ([@dmy046C137]). Taking these data together, kisspeptin may activate the ERK1/2 signaling via the β-arrestin 1, β-arrestin 2 and PLC--PKC-ERK1/2 signaling pathways (Figure [2](#dmy046F2){ref-type="fig"}). The experimental results obtained from functional studies showed that kisspeptin activates the PI3K/Akt signaling pathway in a cell type-specific manner. Kisspeptin can induce the phosphorylation of PI3K/Akt in stably *KISS1R*-overexpressed thyroid cancer cells ([@dmy046C117]), but not in rat luteal cells ([@dmy046C95]). Similarly, previous studies demonstrated that kisspeptin-10 promotes the phosphorylation of PI3K/Akt in preoptic neurons ([@dmy046C45]), while kisspeptin-10 suppresses the phosphorylation of PI3K/Akt in tumor cells ([@dmy046C87], [@dmy046C86]; [@dmy046C18]). In fact, kisspeptin-10 does not directly inhibit the activation of PI3K/Akt signaling pathway in tumor cells. The suppressive effect of kisspeptin-10 on PI3K/Akt signaling is mediated by suppressing the capacity of the prometastatic chemokine receptor CXCR4 (the receptor for the chemokine stromal cell-derived factor 1) in response to stromal cell-derived factor 1, which subsequently abolishes the activation of PI3K/Akt signaling by CXCR4 in some tumor cells ([@dmy046C87], [@dmy046C86]).

In tumor cells, numerous studies have documented that kisspeptin inhibits the activity of matrix metalloproteinase-9 (MMP-9) and MMP-2 by blocking nuclear translocation of the nuclear factor κB (NF-κB), which subsequently reduces the capacity of NF-κB to bind to the *MMP-9* promoter ([@dmy046C141]; [@dmy046C37], [@dmy046C44]; [@dmy046C145]; [@dmy046C20]; [@dmy046C125]). Studies have shown that the phosphorylation of ERK and PI3K/Akt is the upstream of NF-κB that regulates the NF-κB DNA-binding activity in tumor cells ([@dmy046C29]; [@dmy046C5]; [@dmy046C69]). Interestingly, the enhanced expression of *MMP-9* and *MMP-2* via the PI3K/Akt/NF-κB ([@dmy046C19]) or ERK/NF-κB signaling pathways ([@dmy046C8]; [@dmy046C58]) has also been identified in different cell types. Collectively, these findings suggest that ERK1/2 or PI3K/Akt signaling is involved in kisspeptin-induced regulation of NF-κB/MMP-9 or NF-κB/MMP-2 (Figure [2](#dmy046F2){ref-type="fig"}). Previous studies have also demonstrated that the administration of kisspeptin suppresses the expression of vascular endothelial growth factor (VEGF) via ERK1/2 signaling, to inhibit angiogenesis in tumors ([@dmy046C21]) and in trophoblast cells ([@dmy046C35]) (Figure [2](#dmy046F2){ref-type="fig"}).

In the past couple of decades, studies have demonstrated the physiological role of kisspeptins and their receptor, KISS1R, in the neuroendocrine-reproductive axis ([@dmy046C27]; [@dmy046C111]), which thereafter revolutionized the field of reproductive physiology. In the meantime, plasma concentrations of kisspeptin-54 were also identified in men and women (pregnant and non-pregnant) ([@dmy046C48]). Interestingly, the plasma concentration of kisspeptin increased dramatically throughout the gestational period ([@dmy046C48]). The clinical data together with the evidence that the *KISS1* gene is greatly expressed in the placenta ([@dmy046C67]; [@dmy046C64]; [@dmy046C83]; [@dmy046C90]) suggest that the plasma kisspeptin during pregnancy is mainly, if not completely, derived from the placental tissue. In the following sections, we gather the latest studies addressing the roles of kisspeptins in early pregnancy, including implantation and placentation, and discuss potential clinical applications.

Expression of kisspeptins and KISS1R in the embryo {#dmy046s10}
==================================================

Although previous studies have reported the expression of kisspeptins and KISS1R in the oocyte ([@dmy046C105]; [@dmy046C32]; [@dmy046C22]), very few studies have documented the expression of this system in the embryo. Using single-cell RNA sequencing (RNA-Seq) analyses, a previous study showed that KISS1R is barely expressed in the human embryo (from the zygote stage to the late blastocyst stage) and in human embryonic stem cells ([@dmy046C142]). To the best of our knowledge, whether kisspeptin is expressed in the embryo has not been reported.

Kisspeptin/KISS1R system in the endometrium {#dmy046s11}
===========================================

Previous studies have indicated that the expression of the kisspeptin/KISS1R system in ovarian cells is affected by the estrous/menstrual cycle ([@dmy046C13]; [@dmy046C39]; [@dmy046C22]; [@dmy046C126]) (for reviews, see [@dmy046C50]). It is most likely that the expression of the kisspeptin/Kiss1r system in the endometrium shares the cycle-dependent changes in different kinds of species. In the human endometrium, a previous study showed that immunostaining of kisspeptin peptides and KISS1R was strong and limited to epithelial cells, with no detection in stromal cells ([@dmy046C14]). Additionally, another study demonstrated that the expression of kisspeptin and KISS1R was present in epithelial cells, though at weak expression levels and was nearly absent in endometrial stromal cells during the proliferative and early secretory phases ([@dmy046C3]) (Table [I](#dmy046TB1){ref-type="table"}). However, the expression of kisspeptin was prominent in endometrial stromal cells in the late secretory phase ([@dmy046C3]), indicating that kisspeptin may function in the decidualized endometrium in preparation for adequate placentation. However, the endometrium showed no significant expression change in kisspeptin peptides and Kiss1r among different ovarian stages in domestic cats ([@dmy046C126]). Interestingly, it has been suggested that kisspeptin-10 expression is higher in the non-pregnant canine uterus compared to the gestational periods investigated ([@dmy046C109]). The same study also suggested that the expression of *Kiss1r* is higher before embryo adhesion than during post-implantation and mid-gestation ([@dmy046C109]), indicating a pregnancy-related down-regulation of the kisspeptin/Kiss1r system in the canine uterus. Additionally, no expression of kisspeptin or KISS1R was observed both in epithelial glands and stromal cells during the menopausal phase in humans ([@dmy046C3]), suggesting that the kisspeptin/KISS1R system may not have a fundamental role in the endometrium at this stage. Table IExpression of *KISS1* and *KISS1R* at the utero-placental interface during mammalian pregnancy.SpeciesCells or tissues reportedTrends across pregnancyReferences**KISS1** HumanvST, vCT, DeciduaDecreased in RSA compared with abortion[@dmy046C138] HumanvST, vCTDecreased in RSA compared with abortion[@dmy046C93] HumanvST; PB and DP (−)Not investigated[@dmy046C77] HumanvCTNot different between term pregnancy and early pregnancy[@dmy046C54] HumanPlacenta (early and term pregnancy, PE)Early pregnancy \> Term pregnancy \> PE[@dmy046C11] HumanPlacenta (term pregnancy, PE); PB and DP (minimal)Term pregnancy \< PE[@dmy046C78] HumanPlacenta (term pregnancy)Circadian rhythm (two surges, 04:00 h and 12:00 h, respectively).[@dmy046C26] HumanvSTNot investigated[@dmy046C48] RatTrophoblast giant cellsGradually decreased[@dmy046C130] HumanvST, vCT; EVTs (−)First trimester \> term pregnancy[@dmy046C7] RatTrophoblast giant cells (gestation Day 16 and Day 22)Day 22 \> Day 16[@dmy046C75] HumanPlacentaPreterm pregnancy \> term pregnancy[@dmy046C134] CatLuminal epithelial cells and uterine glands, stroma cellsNot investigated[@dmy046C126] DogSuperficial uterine glands, SyncytiotrophoblastNot changed between pre-implantation and post-implantation[@dmy046C109] MouseDecidualizing stromal cellsIncreased dynamically from D5 onward[@dmy046C146] HumanEndometriumGlandular endometrium: ectopic \> eutopic[@dmy046C150] HumanEpithelial cells (weak expression levels). ESCs (−)Proliferative stage and early secretory phase[@dmy046C3]ESCs (prominent expression levels)Late secretory phase HumanEndometriumGlandular endometrium: Ectopic \>eutopic, Stromal endometrium: no difference[@dmy046C131] HumanLuminal and glandular epithelial cells, stroma cells (−)Not investigated[@dmy046C14]**KISS1R** HumanvST, vCTDecreased in RSA compared with abortion[@dmy046C138]DeciduasNot different between abortion and RSA HumanvST, vCTNot different between abortion and RSA[@dmy046C93] HumanvST, vCT, EVTs; PB and decidua basalis (−)Not investigated[@dmy046C77] HumanvCT (early pregnancy)First trimester \> term pregnancy[@dmy046C54] HumanPlacenta (early and term pregnancy, PE)Early pregnancy \> PE \> term pregnancy[@dmy046C11] HumanPlacenta, PB and DP (term pregnancy, PE)Not different between term pregnancy and PE[@dmy046C78] RatTrophoblast giant cellsLow expression level[@dmy046C130] HumanvST, vCT, EVTsFirst trimester \> term pregnancy[@dmy046C7] RatPlacenta (gestation Day 16 and Day 22)Day 22 \> Day 16[@dmy046C75] HumanUmbilical vein endothelial cellsNot investigated[@dmy046C100] MouseDecidualizing stromal cellsIncreased from D5 onward[@dmy046C146] CatLuminal epithelial cells and uterine glands. ESCs (−)Not investigated[@dmy046C126] DogSuperficial and deep uterine glandsHigher in pre-implantation than post-implantation[@dmy046C109] DogSyncytiotrophoblast cellsHigher in mid-gestation than post-implantation[@dmy046C109] HumanEpithelial cells. ESCs (−)Week expression levels[@dmy046C3] HumanLuminal and glandular epithelial cells. ESCs (−)Not investigated[@dmy046C14][^1]

Endometriosis is considered a common benign gynecologic disease characterized by the ectopic presence of endometrial tissues (including glandular epithelium and stroma) outside the uterus. A previous study showed that the expression of *KISS1* is significantly higher in the glandular endometrium of endometriosis lesions compared with the eutopic glandular endometrium in patients with or without endometriosis ([@dmy046C131]). Interestingly, there was no significant difference in *KISS1* expression in the stromal endometrium between patients with and patients without endometriosis ([@dmy046C131]), indicating that kisspeptin, known as a suppressor of tumor metastasis, in the glandular endometrium, rather than the stromal endometrium, was potentially implicated in the pathogenesis or maintenance of endometriosis.

Expression of kisspeptins and KISS1R in the placenta {#dmy046s12}
====================================================

Human placenta is a highly specialized organ that forms the interface between the mother and fetus, supplying the fetus with nutrients and excreting waste products from the fetus. The placenta releases metabolic products into the maternal and fetal circulations. In addition, the placenta releases hormones into both the maternal and fetal circulations to modulate multiple gestational functions, including metabolism, fetal growth, parturition and other pregnancy-related functions ([@dmy046C43]). Immediately following implantation, the trophoblast stem cells proliferate and differentiate into two main cell types described as villous and extravillous (for reviews, see [@dmy046C43]; [@dmy046C52]). Non-migratory, villous cytotrophoblast cells (vCTs) fuse to form the multinucleated villous syncytiotrophoblast cells (vSTs), which reside the outer epithelial layer of chorionic villi. As the fundamental functional unit of the placenta, the chorionic villus is responsible for all nutritional-waste exchange between the maternal and the fetal circulation, acting to protect the fetus and exert various endocrine functions (for reviews, see [@dmy046C43]; [@dmy046C52]). Extravillous trophoblast cells (EVTs) eventually differentiate into the placental bed (PB) and endovascular trophoblasts. The PB is responsible for the migration of the embryo into the decidua, and the endovascular trophoblasts are responsible for the uterine spiral artery remodeling ([@dmy046C43]) (Figure [3](#dmy046F3){ref-type="fig"}). However, it is important to note that the differentiation of the placenta in rodents (particularly in the mouse placenta) is quite different from that in humans. Following implantation in mice, the non-polar trophectoderm proliferates and then differentiates into primary trophoblast giant cells, while the polar trophectoderm proliferates and then forms the extraembryonic ectoderm, which further differentiates into the labyrinth and secondary trophoblast giant cells. The labyrinth, named for the intricate network between the mother and fetus, shares similar functions with chorionic villi, such as the transportation of nutrients and endocrine regulation. Both primary and secondary trophoblast giant cells are invasive cells that lead the placenta to attach to the uterus and remodel the uterine vasculature. Therefore, the activities of these cells are similar to those of the EVTs in humans (see reviews [@dmy046C24]; [@dmy046C52]) (Figure [3](#dmy046F3){ref-type="fig"}).

![**Flow diagram demonstrating the different cell lineage pathways involved in murine and human trophoblast differentiation and function.** *KISS1* is mainly expressed in cells of the villous pathway, while *KISS1R* is expressed in cells of both the villous and extravillous pathways. Modified from [@dmy046C52].](dmy046f03){#dmy046F3}

Using Northern blot analysis, a study demonstrated that the expression of *KISS1* mRNA was very weak in the kidney and pancreas but extremely high in the placenta ([@dmy046C68]). However, the expression of *KISS1* mRNA was undetectable in the normal heart, brain, liver, lung and skeletal muscle ([@dmy046C68]). In humans, KISS1R was highly expressed in endocrine tissues, including the placenta, pituitary, pancreas and brain, suggesting a role for the kisspeptin/KISS1R system in the regulation of the endocrine function ([@dmy046C64]; [@dmy046C83]). These early studies strongly suggested that the kisspeptin/KISS1R system may play a fundamental role in regulating the functions of the placenta. More recently, the expression of *KISS1* and *KISS1R* in specific cells within the placenta has been identified, though some studies were inconsistent.

In early pregnancy in humans, the *KISS1* gene is mainly expressed in vCTs ([@dmy046C54]; [@dmy046C48]; [@dmy046C93]; [@dmy046C77]; [@dmy046C138]) but not in EVTs ([@dmy046C7]). As the placenta matures, the expression of *KISS1* is detected in vSTs as well as in the PB ([@dmy046C48]; [@dmy046C77], [@dmy046C78]) (Table [I](#dmy046TB1){ref-type="table"}). Additionally, studies in rats suggested that *Kiss1* is mainly expressed in trophoblast giant cells (similarly to vCTs in humans) and gradually decreases as the placenta matured ([@dmy046C130]; [@dmy046C75]). Nevertheless, many inconsistencies need to be addressed. In humans, it was first identified that there was no significant difference in *KISS1* expression in the placenta between term pregnancy and early pregnancy ([@dmy046C54]). However, later studies indicated that *KISS1* expression is much higher in the placenta in early pregnancy than that in term pregnancy ([@dmy046C7]; [@dmy046C11]). Another study also suggested that *KISS1* expression in the placenta is higher in preterm pregnancy than in term pregnancy ([@dmy046C134]), indicating that *KISS1* expression gradually decreases as the placenta matured. Similarly, *Kiss1* expression gradually decreases during the maturation of the placenta in rats ([@dmy046C130]) (Table [I](#dmy046TB1){ref-type="table"}). Interestingly, *KISS1* expression in human term pregnancy shows a circadian rhythm, with two surges at 04:00 h and 12:00 h each day ([@dmy046C26]). Similar to the expression of the *KISS1* gene in humans, *KISS1R* is also expressed in vCTs in early pregnancy ([@dmy046C54]) and in vSTs during the maturation of the placenta ([@dmy046C7]; [@dmy046C93]; [@dmy046C77]; [@dmy046C138]) (Table [I](#dmy046TB1){ref-type="table"}). However, KISS1R is also located in EVTs ([@dmy046C7]; [@dmy046C77]), the sites where *KISS1* expression was not detected ([@dmy046C7]). The expression level of *KISS1R* in the placenta was higher in the first trimester than in the term pregnancy, indicating that *KISS1R* expression gradually decreases as the placenta matured ([@dmy046C54]; [@dmy046C7]; [@dmy046C11]). Additionally, *KISS1R* expression was not detected in PB ([@dmy046C77]), and it showed a minimal expression level in human term pregnancy ([@dmy046C78]). In combination with the expression pattern of *KISS1* in the placenta, it may be speculated that the kisspeptin/KISS1R system in the placenta mainly functions in early pregnancy in humans in both autocrine and paracrine manners. However, the expression level of Kiss1r is very low in rats ([@dmy046C130]) and islower at Day 16 of pregnancy than at Day 22 of pregnancy [@dmy046C75]. Notably, Kiss1r expression levels in canine placenta is higher in mid-gestation than in post-implantation ([@dmy046C109]) (Table [I](#dmy046TB1){ref-type="table"}). These studies suggest that the role of the kisspeptin/KISS1R system in the placenta was not conserved in different species.

Circulating levels of kisspeptin during pregnancy {#dmy046s13}
=================================================

Because kisspeptin is produced by trophoblasts and because trophoblast invasion is underway 5 days after blastocyst transplantation ([@dmy046C89]), plasma kisspeptin concentrations during the peri-implantation period may reflect early developmental events associated with pregnancy outcome. In humans, the plasma concentration of kisspeptin increases dramatically over the course of pregnancy, with a 900-fold increase in the first trimester and further increases to over 7000-fold in the third trimester compared to the non-pregnant women ([@dmy046C48]). Intriguingly, previous studies in humans have suggested that *KISS1* expression levels in the early placenta and the term placenta do not differ significantly ([@dmy046C54]) or that they are much higher in the early placenta ([@dmy046C7]; [@dmy046C11]). When taking these published data together, it seems that the expression levels of *KISS1* in the placenta of humans may not necessarily reflect the plasma levels of kisspeptin. It is most likely that the increase in the total number of trophoblast cells throughout the course of gestation is responsible for the dramatic increase in serum kisspeptin levels examined. Interestingly, peripheral kisspeptin levels were found to be very low and did not increase during pregnancy in sheep, cows, pigs, rabbits, horses, rhesus monkeys and marmosets, suggesting that the increase in plasma kisspeptin levels during pregnancy may be unique to humans ([@dmy046C4]). However, by using the bovine-specific enzyme immunoassay, recent studies in cows suggested that plasma kisspeptin levels are consistently increased during pregnancy ([@dmy046C81], [@dmy046C82]), indicating that the increase of plasma kisspeptin levels during pregnancy is conserved in cows. Therefore, we may speculate that the detection methods currently used are simply failing to identify kisspeptin proteins in the circulation of certain animals. Future studies performed using species-specific enzyme immunoassay or radioimmunoassay to detect the circulation levels of kisspeptin of related animals will be of great interest. It needs to be noted that kisspeptins are a series of peptides, including kisspeptin-54, kisspeptin-14, kisspeptin-13 and kisspeptin-10 ([@dmy046C64]) (for reviews, see [@dmy046C97]; Hu *et al.*, 2018). These studies seemed to detect only one kisspeptin peptide in the plasma, and the possibility that the antibody used in these studies cross-reacted with other RF amide related-peptides (RFRP), including prolactin-releasing peptide, RFRP1, RFRP2, RFRP3, neuropeptide FF and neuropeptide AF, could not be excluded ([@dmy046C55]). Nevertheless, a previous study using a more specific and sensitive antibody to detect the plasma kisspeptins (including human kisspeptin-54, kisspeptin-14 and kisspeptin-10, rather than one kind of kisspeptin) suggested that plasma kisspeptin levels significantly correlate with gestational age ([@dmy046C55]) (Table [II](#dmy046TB2){ref-type="table"}). Additionally, a very recent study that detected plasma kisspeptin-54 levels in pregnant women suggested the same results ([@dmy046C123]) (Table [II](#dmy046TB2){ref-type="table"}). Therefore, the evidence for the increase in plasma kisspeptin levels during gestation in women seems convincing, at least in humans (Table [II](#dmy046TB2){ref-type="table"}). Future studies need to address the intriguing phenomenon of the increase in plasma kisspeptin levels and the decrease in placental *KISS1* expression levels during gestation in humans. Table IIKisspeptin (KP) concentrations in human plasma or serum during early pregnancy.Pregnancy stateSerum/plasmaKisspeptin (KP)Gestation ageConcentrationReferenceUPSerumKP-546--10 Weeks (*n* = 20)1.50 (0.55--3.72) ng/ml[@dmy046C123]PlasmaKP-546--10 Weeks (*n* = 8)3.52 (1.09--21.7) ng/mlSABSerumKP-546--10 Weeks (*n* = 20)0.20 (0.07--0.37) ng/mlPlasmaKP-546--10 Weeks (*n* = 3)2.7 (0.46--2.7) ng/mlUPPlasmaKP-107--18 Weeks (*n* = 20)5783 (3168--9953) pg/ml[@dmy046C59]MiscarriagePlasmaKP-107--18 Weeks (*n* = 20)391 (152--951) pg/mlUPPlasmaKP-54, 14 and 1011.3 ± 1.9 (*n* = 899)1.06 ± 0.42 pmol/ml[@dmy046C55]MiscarriagePlasmaKP-54, 14 and 109.8 ± 3.1 (*n* = 50)0.42 ± 0.39 pmol/mlUP (twin)PlasmaKP-54, 14 and 1010.7 ± 1.5 (*n* = 20)1.64 ± 0.54 pmol/mlMiscarriage of one fetus (twin)PlasmaKP-54, 14 and 1010.7 ± 1.5 (*n* = 10)1.15 ± 0.58 pmol/mlUP (triplet)PlasmaKP-54, 14 and 1010.7 ± 1.5 (*n* = 2)2.09 ± 0.26 pmol/mlUPPlasmaKP-54, 14 and 109--12 Weeks (*n* = 25)4.51 ± 2.21 nmol/l[@dmy046C15]21--25 Weeks (*n* = 25)10.33 ± 2.65 nmol/l32--36 Weeks (*n* = 25)20.48 ± 7.60 nmol/lGDPlasmaKP-54, 14 and 1021--25 Weeks (*n* = 20)4.51 ± 3.18 nmol/l32--36 Weeks (*n* = 20)11.643 ± 7.65 nmol/lType 1PlasmaKP-54, 14 and 109--12 Weeks (*n* = 16)1.82 ± 1.47 nmol/l21--25 Weeks (*n* = 16)7.12 ± 4.78 nmol/l32--36 Weeks (*n* = 16)16.31 ± 12.10 nmol/lHPlasmaKP-54, 14 and 109--12 Weeks (*n* = 22)1.18 ± 0.36 nmol/l21--25 Weeks (*n* = 22)3.42 ± 1.04 nmol/l32--36 Weeks (*n* = 22)14.14 ± 10.44 nmol/lGHPlasmaKP-54, 14 and 1021--25 Weeks (*n* = 18)8.46 ± 6.24 nmol/l32--36 Weeks (*n* = 18)25.68 ± 9.23 nmol/lPEPlasmaKP-54, 14 and 1021--25 Weeks (*n* = 28)4.46 ± 3.73 nmol/l32--36 Weeks (*n* = 28)16.03 ± 10.09 nmol/lUPPlasmaKP-54, 14 and 10FT (10.4 ± 0.5 Weeks) (*n* = 13)803 ± 125 pmol/l[@dmy046C31]TT (38 ± 0.8 Weeks) (*n* = 7)2483 ± 302 pmol/l15 d postpartum (*n* = 7)\<2 pmol/lMalignant GTNPlasmaKP-54, 14 and 10Pre-therapy (*n* = 11)1363 ± 1076 pmol/lPost-therapy (*n* = 11)\<2 pmol/lUPPlasmaKP-54, 14 and 10TT (34 ± 0.6) (*n* = 49)13 783 ± 864 pmol/l[@dmy046C56]SalivaryKP-54, 14 and 10TT (34 ± 0.6) (*n* = 49)123 ± 34 pmol/lUrineKP-54, 14 and 10TT (34 ± 0.6) (*n* = 49)301 ± 59 pmol/lUPPlasmaKP-54FT (*n* = 11)1230 ± 346 pmol/l[@dmy046C48]ST (*n* = 16)4590 ± 555 pmol/lTT (*n* = 12)9590 ± 1640 pmol/l5 d postdelivery (*n* = 10)7.63 ± 1.33 pmol/lUP (singleton)SerumKP-5411--14 Weeks (*n* = 31)1995 ± 375 pmol/l[@dmy046C149]PE (singleton)SerumKP-5411--14 Weeks (*n* = 30)1554 ± 385 pmol/lUP (singleton)PlasmaKP-54TT (*n* = 50)9.69 ± 1.35 ng/ml[@dmy046C1]Mild PEPlasmaKP-54TT (*n* = 15)2.61 ± 0.40 ng/mlSevere PEPlasmaKP-54TT (*n* = 24)1.17 ± 0.24 ng/mlUP (singleton)PlasmaKP-1016 Weeks (*n* = 158)1044 ± 621 pmol/l[@dmy046C72]28 Weeks (*n* = 139)1714 ± 1306 pmol/l36 Weeks (*n* = 99)2441 ± 2123 pmol/lUPSerumKP-1016--20 Weeks (*n* = 317)1188 (494--2298) pg/ml[@dmy046C148]UPSerumKP-1016--20 Weeks (*n* = 118)1164 (442--3903) pg/mlPESerumKP-1016--20 Weeks (*n* = 57)1109 (605--1935) pg/mlUPSerumKP-1038.03 ± 0.06 (*n* = 30)1.66 ± 0.59 ng/ml[@dmy046C78]Cord serum0.58 ± 0.39 ng/mlPESerumKP-1032.95 ± 0.53 (*n* = 19)2.03 ± 0.44 ng/mlCord serum1.78 ± 0.38 ng/mlUPPlasmaKP-108--14 Weeks (*n* = 31)2035 ± 1260 pmol/l[@dmy046C114]SGAPlasmaKP-108--14 Weeks (*n* = 31)1376 ± 1317 pmol/l[^2][^3]

Kisspeptins and embryo implantation {#dmy046s14}
===================================

In endometrial tissues in mice, kisspeptin can trigger the phosphorylation of p38 and ERK1/2 in the uterus on D4 of pregnancy ([@dmy046C34]), suggesting that kisspeptin/KISS1R may affect the function of the endometrium in mice. Additionally, the expression of *Kiss1* and *Kiss1r* mRNA gradually increases with the progression of stromal cell decidualization in the ovariectomized mouse endometrium ([@dmy046C146]). Furthermore, the progression of stromal cell decidualization was significantly blocked when the expression of *Kiss1* was attenuated by small interfering RNAs ([@dmy046C146]). A previous study indicated that kisspeptin treatment increased mouse blastocyst adhesion to collagens ([@dmy046C127]), possibly through the down-regulation of MMP (particularly MMP-2 and MMP-9) activity via the ERK1/2 and protein kinase C signaling pathways ([@dmy046C28]; [@dmy046C79]; [@dmy046C127]). These studies suggest that the kisspeptin/KISS1R system acts at both the blastocyst and endometrium to facilitate the process of embryo implantation (Figure [4](#dmy046F4){ref-type="fig"}). The ablation of *kiss1* gene (*Kiss1* -/-) led to hypogonadism and infertility in female mice ([@dmy046C36]; [@dmy046C66]), while acute replacement of gonadotropins and estradiol restored ovulation, mating and fertilization ([@dmy046C10]). However, these hormone-rescued mice were still unable to achieve pregnancy because the embryos (*Kiss1* +/**−**) failed to implant ([@dmy046C10]). Furthermore, the same study demonstrated that embryos (*Kiss1* +/**−**) successfully implanted in the uterus of a wild-type recipient female, suggesting that the inability to implant was due to a maternal factor but not an embryonic defect of the kisspeptin/KISS1R signaling ([@dmy046C10]). Leukemia inhibitory factor (LIF) is a cytokine that is required for implantation in mice ([@dmy046C6]; [@dmy046C122]). The uterine gland-derived LIF initiates embryo-uterine communication, leading to embryo attachment and stromal cell decidualisation ([@dmy046C113]; [@dmy046C60]). In a murine *Kiss1* (−/−) model, LIF is weakly expressed in the uterine glands on the day of implantation, and exogenous LIF treatment in hormone-primed *Kiss1* (−/−) female mice partially rescued implantation ([@dmy046C10]). These data suggest that kisspeptin is the upstream regulator of LIF; the mechanism by which kisspeptin affects the process of implantation is by up-regulating LIF levels. Furthermore, estrogen rapidly up-regulated uterine LIF expression, further demonstrating that supplementation with LIF restores decidualisation and implantation in uterine estrogen receptor-ablated mice ([@dmy046C25]; [@dmy046C94]) and ovariectomized mice ([@dmy046C17]). However, in the *Kiss1* knockout mouse, although LIF partially rescued implantation failure, E2 failed to do so ([@dmy046C10]), suggesting that *Kiss1* may either lie downstream of E2 or cooperate with E2 in triggering *Lif* expression. The former is more likely, as the expression of *Kiss1* mRNA was up-regulated after E2 treatment in the mouse endometrium ([@dmy046C146]). Together, these studies indicated that the E2-kisspeptin-LIF pathway regulates the process of implantation. Interestingly, clinical studies indicated that deficiency of plasma kisspeptin on the hCG day in females with unexplained infertility was associated with a reduced likelihood of implantation after ICSI ([@dmy046C53]; [@dmy046C84]). However, it is obvious that plasma kisspeptin is not derived from placenta and that plasma kisspeptin levels on the hCG day barely reflect levels at the maternal-fetal interface. Nevertheless, it is most likely that the locally produced kisspeptin affects the level of LIF in the endometrium and the subsequent implantation rate ([@dmy046C4]).

![**A schematic diagram showing how the kisspeptin/KISS1R system regulates the processes of embryo implantation and placentation**. Kisspeptin promotes embryo adhesion to the endometrium and stroma decidualization by up-regulating cell adhesion molecules and LIF, respectively. Kisspeptin inhibits trophoblast invasion and angiogenesis via the down-regulation of MMPs and VEGFA, respectively. VEGFA, vascular endothelial growth factor A; MMPs, matrix metalloproteinases; LIF, leukemia inhibitory factor.](dmy046f04){#dmy046F4}

Kisspeptins and trophoblast invasion {#dmy046s15}
====================================

The process of hemochorial placentation bears a striking resemblance to cancer invasion. However, placental development is well-organized and physiological, while cancer invasion is chaotic and pathological. There are several similarities in their respective capacities, including increased cellular proliferation, reduced cell death, increased blood supply and invasion of local tissues (summarized in [@dmy046C74]). It was first reported in 2002 that the expression levels of *KISS1* and *KISS1R* detected by quantitative polymerase chain reaction analysis of laser capture microdissection specimens are largely increased in human placenta ([@dmy046C54]). Additionally, higher *KISS1R* expression levels were found in the early placenta, where the invasive capacity of trophoblasts needs to be tightly controlled compared to the term placenta ([@dmy046C54]). This was the first evidence that suggested the potential role of the kisspeptin/KISS1R system in the invasive and migratory properties of trophoblast cells. One year later, a study demonstrated the localization of *KISS1* mRNA and kisspeptin peptide immunoreactivity in the placental syncytiotrophoblasts of humans, suggesting that the dramatic increase in plasma kisspeptin levels during pregnancy was derived from placenta ([@dmy046C48]). Intriguingly, among the four kisspeptins, only kisspeptin-10 resulted in an increase of intracellular Ca^2+^ in trophoblast cells of the early placenta and subsequently inhibited trophoblast migration but not proliferation, indicating that kisspeptin-10 is the physiological activator of KISS1R in human placenta ([@dmy046C7]). The same study also demonstrated that kisspeptin-10 triggered a decrease in collagenase activity and reduced the activity of MMP-2 in a dose-dependent manner, which resulted in the attenuation of trophoblast migration ([@dmy046C7]). In agreement, a recent study showed that kisspeptin-10 treatment reduced MMP-2 expression in primary trophoblast cells and subsequently reduced the migratory capability of trophoblast cells using a scratch-migration assay ([@dmy046C35]). The same study also demonstrated that kisspeptin-10 inhibited the expression of MMP-1, 3, 7, 9, 10 and 14 as well as VEGF and increased the expression of tissue inhibitors of metalloproteinases 1 and 3 in primary trophoblast cells ([@dmy046C35]). These effects were probably mediated via the ERK1/2 signaling pathway, as kisspeptin-10 treatment significantly induced ERK1/2 phosphorylation, while co-treating the cells with a kisspeptin antagonist almost completely blocked the activation of ERK1/2 ([@dmy046C35]). Interestingly, kisspeptin also exerted an anti-invasive effect on EVTs. A previous study indicated that kisspeptin induces the increased adhesion of human EVTs to type-I collagen in a dose- and time-dependent manner, which is a major component of the human placenta ([@dmy046C127]). This effect was mediated via the PKC and ERK1/2 pathways, as the inhibition of both PKC and ERK1/2 attenuated the kisspeptin-dependent increase in EVT adhesion ([@dmy046C127]). In the human placental cell line HTR8/SVneo derived from first trimester EVTs, the expression levels of *KISS1* and *KISS1R* regarding both mRNA and protein levels are significantly lower than those in primary trophoblast cells ([@dmy046C76]). Nevertheless, treatment with kisspeptin-10 led to the phosphorylation of ERK1/2 in the HTR8/SVneo cells ([@dmy046C103]), suggesting that the kisspeptin-activated ERK1/2 signaling pathway is conserved in EVTs as well as in cell lines derived from EVTs. Additionally, kisspeptin-10 inhibited the migration of HTR8/SVneo cells by stimulating complex ERK1/2-p90rsk-GSK3 beta-FAK feedback interactions ([@dmy046C103]). Intriguingly, the kisspeptin/KISS1R system negatively regulated cell proliferation in bovine placental cotyledon cell lines isolated at the first trimester of pregnancy, which was not observed in human trophoblast cells ([@dmy046C76]). However, in human umbilical vein endothelial cells (HUVEC), kisspeptin-10 treatment induced the concentration-dependent inhibition of cell proliferation and migration but did not affect HUVEC cell viability or apoptosis ([@dmy046C100]).

Taking these data together, we may draw a conclusion that kisspeptin/KISS1R signaling inhibits the migration of both trophoblast cells and EVTs via the activation of ERK1/2 and the suppression of MMP expression and activity. Therefore, kisspeptin/KISS1R signaling inhibits the proliferation of several cell types derived from placenta, but not that of human trophoblast cells.

Genetic mutations of *KISS1* and *KISS1R* {#dmy046s16}
=========================================

In humans, kisspeptin was initially implicated in the onset of puberty as two independent research groups reported *KISS1R* gene mutations in patients with idiopathic hypogonadotropic hypogonadism (IHH) ([@dmy046C27]; [@dmy046C111]). Subsequently, heterozygous and homozygous *KISS1* mutations have also been identified in patients with IHH ([@dmy046C16]; [@dmy046C133]). Interestingly, women with heterozygous *KISS1* or *KISS1R* mutations were able to deliver their babies with homozygous *KISS1* or *KISS1R* mutations ([@dmy046C91]; [@dmy046C133]) (Table [III](#dmy046TB3){ref-type="table"}). These results suggested that carrying heterozygous mutations in *KISS1* or *KISS1R* does not appear to limit subsequent uterine and placental function. Additionally, a case report showed that a woman with homozygous *KISS1R* mutations had a normal vaginal delivery of a healthy child with a normal birthweight ([@dmy046C91]). Similarly, *Kiss1* (+/**−**) and *Kiss1r* (+/**−**) female mice were able to carry the normal weight of fetus with homozygous *KISS1* mutations and there was no significant harmful effect on placental function ([@dmy046C47]). These results indicate that the functional role of the kisspeptin/KISS1R system in the placenta could be compensated by other factors during early pregnancy. However, global ablation of *Kiss1* or *Kiss1r* led to dramatically suppressed uterine growth and almost entirely prevented adenogenesis ([@dmy046C70]) and caused subsequent infertility ([@dmy046C36]; [@dmy046C66]), although *Kiss1* (+/**−**) or *Kiss1r* (+/**−**) phenotypes were fertile ([@dmy046C111]; [@dmy046C66]; [@dmy046C38]; [@dmy046C47]). Even though E2 treatment in *Kiss1* (**−**/**−**) mice and/or genetic restoration of kisspeptin signaling in GnRH neurons in *Kiss1r* (**−**/**−**) mice fully rescued the uterine growth, functional adenogenesis in the endometrium was only partially restored ([@dmy046C70]). Therefore, while uterine growth is mainly contingent on E2-output via kisspeptin signaling in GnRH neurons, local kisspeptin signaling in the endometrium is essential for normal endometrial adenogenesis and functions. Furthermore, embryos failed to implant in maternal mice with homozygous *Kiss1* mutations ([@dmy046C10]). These results seem to support the fundamental role of maternal kisspeptin/Kiss1r system in preparation for embryo implantation, at least in mice. Table IIISummary of the effect of Kiss1/Kiss1r in genetically modified or mutant models (placental specific knockout or overall knockout) on fertility or placental function.Knockout modelSpeciesFertility or placental functionReferences*Kiss1*+/− or *Kiss1*−/−; *Kiss1r*+/− or *Kiss1r*−/− (fetus)MouseNormal weight of fetus and placenta, normal nutrient transfer function of placenta at E15.5 days[@dmy046C47]*Kiss1*+/− or *Kiss1*r+/− (maternal)MouseFertile[@dmy046C47]*Kiss1*−/− (maternal)MouseFail to implant and infertile[@dmy046C10]*Kiss1r*−/− (maternal)MouseInfertile[@dmy046C36]*Kiss1r*+/− (maternal)MouseFertile[@dmy046C111]*Kiss1r*−/− (maternal)MouseInfertile[@dmy046C111]*Kiss1r*+/− (maternal)MouseFertile before 48-week-old\
Infertile at 48-week-old[@dmy046C38]*Kiss1*+/− (maternal)MouseFertile[@dmy046C16]*Kiss1*+/− *or Kiss1r*+/− (maternal)MouseFertile[@dmy046C66]*Kiss1*−/− *or Kiss1r*−/− (maternal)MouseInfertile[@dmy046C66]*Kiss1*−/− *or Kiss1r*−/− (maternal)MouseUterine growth suppressed and adenogenesis nearly stopped[@dmy046C70]*KISS1R*+/− (maternal), *KISS1R*−/− (maternal) *and KISS1R*−/− (fetus)HumanFertile[@dmy046C91]*KISS1*+/− (maternal) and *KISS1*−/− (fetus)HumanFertile[@dmy046C133]

Kisspeptins and early pregnancy viability {#dmy046s17}
=========================================

Since kisspeptins are mainly derived from placenta, the levels of plasma or serum kisspeptin can probably act as a marker for the function of the placenta and therefore pregnancy viability. Miscarriage is the most common early pregnancy complication as it affects 20% of recognized pregnancies, with a potentially devastating impact on pregnant women ([@dmy046C107]; [@dmy046C85]) (for reviews, see [@dmy046C96]). As miscarriages (except threatened miscarriage) are sometimes irreversible, prevention is probably the only way to intervene in this problem. One possible approach is to develop biochemical markers that have high accuracy to predict or diagnose the occurrence of abortion. Accumulating evidence has suggested that plasma or serum kisspeptin (kisspeptin-10 or kisspeptin-54) levels show excellent accuracy to discriminate confirmed miscarriage from intrauterine pregnancy at the time of diagnosis ([@dmy046C59]; [@dmy046C55]; [@dmy046C106]; [@dmy046C123]). To discriminate miscarriage from viable intrauterine pregnancy, one study detected kisspeptin-54 in both serum and plasma samples ([@dmy046C123]), while another study detected kisspeptin-54, kisspeptin-14 and kisspeptin-10 in plasma samples ([@dmy046C55]). Nevertheless, both studies performed adequate statistical analysis to control for possible confounders, including gestational and maternal age. Both studies suggested that kisspeptin levels were significantly lower in the miscarriage group than in the intrauterine pregnancy group. Compared with the serum β-hCG levels, the plasma kisspeptin levels had a higher diagnostic performance for miscarriage. Furthermore, combined kisspeptin and β-hCG measurements had similar diagnostic accuracy compared with kisspeptin measurement alone ([@dmy046C55]). It is interesting to determine whether there is a relationship between serum or plasma kisspeptin and β-hCG levels depending on the pregnancy state. Although plasma kisspeptin levels were positively associated with several placenta-derived hormones (including progesterone, estradiol and human prolactin), plasma kisspeptin levels and β-hCG levels were not significantly associated ([@dmy046C55]; [@dmy046C48]). Consonantly, a most recent linear regression analysis performed using clinical samples showed that serum levels of kisspeptin and β-hCG were positively associated in women with miscarriages (at estimated gestational age 6--10 weeks), whereas there was no significant association between serum levels of kisspeptin and β-hCG in women with viable pregnancies ([@dmy046C123]). These data strongly suggest that kisspeptin levels can be considered as a new potential marker for early pregnancy viability and may have clinical utility in developing an accurate test of early pregnancy outcome in the future. A prospective cohort study is necessary to confirm the applicability of the serum or plasma kisspeptin assay for predicting or diagnosing miscarriage. Furthermore, it is also necessary to compare the kisspeptin assay with other potential biomarkers, including β-hCG ([@dmy046C55]), or their combination in predicting early pregnancy outcome. It should also be noted that the expression of *KISS1* in the placenta or plasma kisspeptin levels may be affected by the adverse uterine environment that could lead to abortion ([@dmy046C139]; [@dmy046C123]). Therefore, it needs to be further determined whether plasma kisspeptin levels could be considered as a marker to evaluate early pregnancy outcome in abnormal conditions.

Kisspeptins and gestational trophoblastic neoplasia {#dmy046s18}
===================================================

The highest *KISS1* expression levels in the placenta were found during the first trimester in humans ([@dmy046C7]; [@dmy046C11]) and during embryo Day 12.5 in rodents ([@dmy046C130]; [@dmy046C4]). The expression pattern of *KISS1* coincides with the time of peak trophoblast invasion when the regulation of this process is of critical importance ([@dmy046C4]). In humans, *KISS1* is mainly expressed in the villous trophoblast and has an inhibitory role in trophoblast migration through a paracrine/autocrine mechanism within the placental tissue ([@dmy046C7]; [@dmy046C103]; [@dmy046C127]). Therefore, the change in the local expression of *KISS1* in the placenta may be involved in some invasion-dysregulated diseases.

Gestational trophoblastic neoplasia (GTN) is a spectrum of both benign and malignant gestational tumors, including complete mole, partial hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor ([@dmy046C73]; [@dmy046C9]). Plasma β-hCG levels have been widely used to predict the prognosis of malignant GTN before, during or after chemotherapy ([@dmy046C143], [@dmy046C144]). Previous studies showed that the expression levels of *KISS1* and *KISS1R* were significantly increased in molar pregnancies (a benign GTN), but the expression levels of *KISS1* and *KISS1R* were decreased in choriocarcinoma cells (malignant GTN cells) ([@dmy046C54]). These results strongly indicate that down-regulation of the placental expression of *KISS1* is involved in the malignant invasion. Intriguingly, plasma kisspeptin levels (including kisspeptin-54, kisspeptin-14 and kisspeptin-10) in patients with malignant GTN were elevated ([@dmy046C31]). This study supported the notion that the expression levels of *KISS1* in the placenta may not necessarily reflect the plasma levels of kisspeptin, and the increase in serum kisspeptin levels could be explained by the dramatic increase of malignant trophoblast cells. Additionally, plasma kisspeptin levels in GTN patients fell during and after treatment with chemotherapy ([@dmy046C31]), indicating that plasma kisspeptin levels could be used to predict the prognosis of malignant GTN during or after chemotherapy. Interestingly, the plasma kisspeptin levels strongly and positively correlated with plasma β-hCG levels (*r*^2^ = 0.99, *P* \< 0.0001) in patients with malignant GTN before, during or after chemotherapy ([@dmy046C31]), suggesting that kisspeptin and β-hCG in the blood were derived from the same tissue and showed similar secretion pulses in cases of malignant GTN. It would be of great interest for future studies to compare plasma or serum kisspeptin levels with serum β-hCG levels regarding their sensitivity and specificity of predicting the prognosis of malignant GTN (before, during or after chemotherapy).

Unanswered questions and future perspectives {#dmy046s19}
============================================

Although the anti-invasive effect of kisspeptin and kisspeptin levels during early pregnancy have been thoroughly discussed in this review, many formidable questions remain to be addressed. The expression of *KISS1* or *KISS1R* was increased in some tumors of advanced stage ([@dmy046C51]; [@dmy046C110]; [@dmy046C62], [@dmy046C63]; [@dmy046C108]). It is likely that the kisspeptin/KISS1R system is increased to prevent further tumor invasiveness and the formation of local or distant metastasis. In support of this hypothesis, the expression of *KISS1* or *KISS1R* in placental tissues was higher in early pregnancy when the invasion was higher than that in term pregnancy ([@dmy046C54]; [@dmy046C7]; [@dmy046C134]; [@dmy046C11]) (Table [I](#dmy046TB1){ref-type="table"}). Nevertheless, until now, no direct evidence has confirmed this hypothesis. Future studies are required to investigate whether overexpression of the kisspeptin/ KISS1R system can attenuate the metastasis and/or invasiveness of tumor cells as well as trophoblast cells.

The concentrations of kisspeptin detected in serum samples are significantly lower than those detected in plasma ([@dmy046C99]). Additionally, the collection tube type, processing time and storage condition of samples can also affect the kisspeptin concentrations examined. Therefore, a standardized sample collection method for the measurement of serum or plasma kisspeptin levels should be established if kisspeptin levels are to be used as markers for pregnancy or for other use. It remains possible that the plasma kisspeptin (kisspeptin-10 or kisspeptin-54) measured in pregnant patients is not, in fact, kisspeptin but several cross-reacting peptides, such as RFRP1, RFRP2, RFRP3, neuropeptide FF and neuropeptide AF. Furthermore, since all kisspeptins, including kisspeptin-54, kisspeptin-14, kisspeptin-13 and kisspeptin-10, have high-affinity binding and activation of KISS1R ([@dmy046C64]; [@dmy046C90]), it is better to detect all these peptides rather than one single peptide. A measurement method of great sensitivity and specificity has been shown to detect kisspeptin levels, including kisspeptin-54, kisspeptin-14 and kisspeptin-10 ([@dmy046C30]; [@dmy046C55]). In fact, kisspeptin-13 shares the C-terminal decapeptide motif with other isoforms of kisspeptin, which is most likely to have cross-reaction with kisspeptin-10. Future studies performed using mass spectrometry analyses or other proteomics to differentiate different kisspeptin isoforms will be of great interest. At present, the ratio of these kisspeptins in the blood is still unknown.

Although plasma or serum kisspeptin levels are significantly increased in early pregnancy compared to non-pregnant controls ([@dmy046C48]; [@dmy046C55]; [@dmy046C123]), the time at which plasma or serum kisspeptin levels start to increase has not been investigated. It would be of great interest to compare the sensitivity and specificity of the diagnosis of early pregnancy between plasma or serum kisspeptin levels and serum β-hCG levels. It has been suggested that the urine kisspeptin:creatinine ratios are higher in pregnant women compared to non-pregnant women in the third trimester ([@dmy046C56]), indicating that kisspeptin could be released in the urine and be measured as a potential marker. Whether the urine kisspeptin:creatinine ratio is up-regulated in the early pregnancy has not been investigated. If it is true, could this ratio or kisspeptin levels be more specific and sensitive than the urine β-hCG levels to detect early pregnancy? Most likely, urine kisspeptin levels or urine kisspeptin:creatinine ratio may be used as a new screening method to detect early pregnancy.

The incompatible change in plasma or serum kisspeptin levels and the expression of *KISS1* in placental tissue during pregnancy in humans are still unexplained based on previous studies. It seems that the expression of *KISS1* in the placenta may not necessarily reflect the plasma levels of kisspeptin, at least in humans. Most likely, the placenta-derived kisspeptins are not immediately secreted in the bloodstream after they are produced and modified within the cells in the placenta. It is also likely that the kisspeptins in the blood are derived from other organs or tissues during late pregnancy. More studies are needed to elucidate this interesting phenomenon in humans or other animals, if this phenomenon does exist.

With regard to miscarriage and GTN, a prospective cohort study is necessary to explore the sensitivity and specificity of plasma kisspeptin levels in predicting these diseases or newborn health. A large-scale study to define the normal range of plasma and serum kisspeptin levels during early pregnancy will be greatly helpful. Furthermore, it is also necessary to compare the kisspeptin assay with other potential biomarkers, such as β-hCG, or their combination in predicting early pregnancy outcome. Additional studies should investigate the kisspeptin levels in other placenta-related diseases, such as placenta previa and placenta accreta/increta/percreta. Future studies focused on the kisspeptin levels in women with assisted reproduction will also be of great importance. To the best of our knowledge, the applicability of the serum or plasma kisspeptin assay in other pregnancy outcomes, such as multiple pregnancy and ectopic pregnancy, has not been investigated.

Pre-eclampsia, a pregnancy-induced complication characterized by the de-novo development of concurrent hypertension and proteinuria, remains the second leading cause of maternal death ([@dmy046C118]). Recent studies implicated a possible role of kisspeptin in predicting and diagnosing pre-eclampsia ([@dmy046C1]; [@dmy046C15]; [@dmy046C78]; [@dmy046C147]). Plasma kisspeptin-10 levels were negatively correlated with the severity of disease ([@dmy046C1]), but the potential mechanism for kisspeptin signaling in this disease has not been fully investigated. The defect of placental angiogenesis has been thought to be involved in pre-eclampsia ([@dmy046C71]; [@dmy046C121]) and related to the severity of the disease as well as perinatal outcome ([@dmy046C120], [@dmy046C119]). It is likely that the inhibition of new vessel sprouting from placental vessels by kisspeptin is involved in the pathogenesis of pre-eclampsia ([@dmy046C100]; [@dmy046C35]). Indeed, a clinical study showed that plasma kisspeptin-10 levels were lower in women with pre-eclampsia and inversely correlated with the severity of pre-eclampsia ([@dmy046C147]). The same study also showed that the maternal plasma kisspeptin-10 levels were correlated with the estimated fetal weight in the uterus during the second and the third trimesters ([@dmy046C147]). Furthermore, kisspeptin levels (16 weeks) in maternal plasma were positively correlated with the birthweight of fetuses in uncomplicated pregnancies ([@dmy046C114]; [@dmy046C72]). These studies strongly suggested that plasma kisspeptin levels were an emerging biomarker for impaired utero-placental perfusion and intrauterine growth restriction.

Conclusion {#dmy046s20}
==========

We conducted literature reviews regarding the coordinated spatial and temporal expression patterns of kisspeptins and their functional receptors during embryo implantation and early human gestation. We also provided an overview of the available evidence, indicating a potential role of kisspeptin as an emerging marker in early pregnancy and a diagnostic or therapeutic target in pregnancy-related diseases. Admittedly, the conclusive demonstration of plasma, serum or urine kisspeptin levels as potential markers for early pregnancy-related diseases is still pending. In addition, the diagnostic utility and therapeutic target of kisspeptin in early pregnancy or placenta-related diseases have not been fully investigated. Thus, there are many unsolved problems that exist and are far from elucidated.
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[^1]: Abbreviations: RSA, recurrent spontaneous abortion; vST, villous syncytiotrophoblasts; vCT, villous cytotrophoblasts; EVTs, extravillous trophoblast cells; ESCs, endometrial stroma cells; DP, decidua parietalis; PB, placental bed.

[^2]: Abbreviations: UP, uncomplicated pregnancy; GD, gestational diabetes mellitus; type 1, pre-gestational insulin-dependent diabetes mellitus; H, chronic hypertension; GH, gestational hypertension; PE, pre-eclampsia; SGA, restriction small for gestational age; FT, the first trimester; ST, the second trimester; TT, the third trimester.

[^3]: Median ± SD or Median (quartile range) \[range\].
